Oral multi-targeted tyrosine kinase inhibitor formulation administered in oncology settings for renal cell carcinoma and gastrointestinal stromal tumor management. Pharmaceutical manufacturers supply to hospitals, oncology clinics, and distributors for procurement by healthcare providers treating advanced cancers.